Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways

International Journal of Cancer

Volumn 134, Issue 12, 2014, Pages 2853-2864

  Raber, Patrick L ^a   Thevenot, Paul ^a   Sierra, Rosa ^a   Wyczechowska, Dorota ^a   Halle, Daniel ^a   Ramirez, Maria E ^a   Ochoa, Augusto C ^a   Fletcher, Matthew ^a   Velasco, Cruz ^a   Wilk, Anna ^a   Reiss, Krzysztof ^a   Rodriguez, Paulo C ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

eNOS; MDSC; peroxynitrites

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PEROXYNITRITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVITY; CELL TYPE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GRANULOCYTIC MYELOID DERIVED SUPPRESSOR CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTIC INFILTRATION; MOLECULAR DYNAMICS; MONOCYTIC MYELOID DERIVED SUPPRESSOR CELL; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SUPPRESSOR CELL;

ENOS; MDSC; PEROXYNITRITES;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GRANULOCYTES; HUMANS; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MONOCYTES; NADPH OXIDASE; NEOPLASMS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; NITRITES; PEROXYNITROUS ACID; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 84897992390     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28622     Document Type: Article

References (45)

1. Coussens LM, Zitvogel L, Palucka AK,. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 2013; 339: 286-91.
2. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V,. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12: 253-68.
3. Raber P, Ochoa AC, Rodriguez PC,. Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives. Immunol Invest 2012; 41: 614-34.
4. Gabrilovich DI, Nagaraj S,. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-74.
5. Greten TF, Manns MP, Korangy F,. Myeloid derived suppressor cells in human diseases. Int Immunopharmacol 2011; 11: 802-7.
6. Gabrilovich DI, Bronte V, Chen SH, et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res 2007; 67: 425.
7. Rodriguez PC, Ernstoff MS, Hernandez C, et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 2009; 69: 1553-60.
8. Rodriguez PC, Quiceno DG, Zabaleta J, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004; 64: 5839-49.
9. Srivastava MK, Sinha P, Clements VK, et al. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 2010; 70: 68-77.
10. Kusmartsev S, Gabrilovich DI,. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol 2005; 174: 4880-91.
11. Jayaraman P, Parikh F, Lopez-Rivera E, et al. Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release. J Immunol 2012; 188: 5365-76.
12. Kusmartsev S, Nefedova Y, Yoder D, et al. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 2004; 172: 989-99.
13. Corzo CA, Cotter MJ, Cheng P, et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol 2009; 182: 5693-701.
14. Lu T, Ramakrishnan R, Altiok S, et al. Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J Clin Invest 2011; 121: 4015-29.
15. Bronte V, Apolloni E, Cabrelle A, et al. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 2000; 96: 3838-46.
16. Nagaraj S, Gupta K, Pisarev V, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 2007; 13: 828-35.
17. Yang GY, Taboada S, Liao J,. Induced nitric oxide synthase as a major player in the oncogenic transformation of inflamed tissue. Methods Mol Biol 2009; 512: 119-56.
18. Kasic T, Colombo P, Soldani C, et al. Modulation of human T-cell functions by reactive nitrogen species. Eur J Immunol 2011; 41: 1843-9.
19. Hess DT, Stamler JS,. Regulation by S-nitrosylation of protein post-translational modification. J Biol Chem 2012; 287: 4411-8.
20. Molon B, Ugel S, Del PF, et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med 2011; 208: 1949-62.
21. Brito C, Naviliat M, Tiscornia AC, et al. Peroxynitrite inhibits T lymphocyte activation and proliferation by promoting impairment of tyrosine phosphorylation and peroxynitrite-driven apoptotic death. J Immunol 1999; 162: 3356-66.
22. Bronte V, Kasic T, Gri G, et al. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med 2005; 201: 1257-68.
23. De SC, Serafini P, Marigo I, et al. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci USA 2005; 102: 4185-90.
24. Norell H, Martins da PT, Lesher A, et al. Inhibition of superoxide generation upon T-cell receptor engagement rescues Mart-1(27-35)-reactive T cells from activation-induced cell death. Cancer Res 2009; 69: 6282-9.
25. Rodriguez PC, Hernandez CP, Quiceno D, et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 2005; 202: 931-9.
26. Batinic-Haberle I, Cuzzocrea S, Reboucas JS, et al. Pure MnTBAP selectively scavenges peroxynitrite over superoxide: comparison of pure and commercial MnTBAP samples to MnTE-2-PyP in two models of oxidative stress injury, an SOD-specific Escherichia coli model and carrageenan-induced pleurisy. Free Radic Biol Med 2009; 46: 192-201.
27. Goldstein S, Russo A, Samuni A,. Reactions of PTIO and carboxy-PTIO with*NO,*NO2, and O2-*. J Biol Chem 2003; 278: 50949-55.
28. Rodriguez PC, Ochoa AC,. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev 2008; 222: 180-91.
29. Dietlin TA, Hofman FM, Lund BT, et al. Mycobacteria-induced Gr-1+ subsets from distinct myeloid lineages have opposite effects on T cell expansion. J Leukoc Biol 2007; 81: 1205-12.
30. Movahedi K, Guilliams M, Van den BJ, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008; 111: 4233-44.
31. Youn JI, Nagaraj S, Collazo M, et al. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008; 181: 5791-802.
32. Rafikov R, Fonseca FV, Kumar S, et al. eNOS activation and NO function: structural motifs responsible for the posttranslational control of endothelial nitric oxide synthase activity. J Endocrinol 2011; 210: 271-84.
33. Sinha P, Clements VK, Ostrand-Rosenberg S,. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 2005; 174: 636-45.
34. Van Ginderachter JA, Meerschaut S, Liu Y, et al. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer. Blood 2006; 108: 525-35.
35. Li F, Lu J, Ma X,. Metabolomic screening and identification of the bioactivation pathways of ritonavir. Chem Res Toxicol 2011; 24: 2109-14.
36. Sinha P, Clements VK, Ostrand-Rosenberg S,. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res 2005; 65: 11743-51.
37. Gallina G, Dolcetti L, Serafini P, et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 2006; 116: 2777-90.
38. Bunt SK, Yang L, Sinha P, et al. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 2007; 67: 10019-26.
39. Sinha P, Clements VK, Bunt SK, et al. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 2007; 179: 977-83.
40. Haile LA, Gamrekelashvili J, Manns MP, et al. CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice. J Immunol 2010; 185: 203-10.
41. Highfill SL, Rodriguez PC, Zhou Q, et al. Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. Blood 2010; 116: 5738-47.
42. Marigo I, Bosio E, Solito S, et al. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 2010; 32: 790-802.
43. Youn JI, Kumar V, Collazo M, et al. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat Immunol 2013; 14: 211-20.
44. Zea AH, Rodriguez PC, Atkins MB, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005; 65: 3044-8.
45. Solito S, Falisi E, az-Montero CM, et al. A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood 2011; 118: 2254-65.